-
Mashup Score: 0Teprotumumab: TED treatment shows benefits for patients - 1 hour(s) ago
Retreatment rates are lower, with few orbit decompression procedures.
Source: www.ophthalmologytimes.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 0
Data caps reflect “highly competitive environment,” cable lobby tells FCC.
Source: arstechnica.comCategories: General Medicine News, General HCPsTweet-
Cable companies and Trump’s FCC chair agree: Data caps are good for you - Ars Technica https://t.co/xLRvvfy5Hc
-
-
Mashup Score: 3Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers - 1 hour(s) ago
Sacituzumab tirumotecan monotherapy demonstrated antitumor activity with a manageable safety profile in previously treated endometrial and ovarian cancers.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers @myESMO #ESMO24 #gynsm #ovca #oncology https://t.co/dExp7EVjQO
-
-
Mashup Score: 2Natural Evolution of Incomplete Reperfusion in Patients following Endovascular Therapy after Ischemic Stroke | Stroke - 1 hour(s) ago
Background: A third of endovascularly treated stroke patients experience incomplete reperfusion (expanded Thrombolysis in Cerebral Infarction, eTICI<3) and the natural evolution of this incomplete reperfusion remains unknown. We systematically reviewed literature and performed a meta-analysis on the natural evolution of incomplete reperfusion after endovascular therapy. Methods: A systematic review of MEDLINE, Embase and PubMed up until March 1, 2024 using a predefined strategy. Only full-text English written articles reporting rates of either favorable (i.e., delayed reperfusion or no new infarct) or unfavorable progression (i.e., persistent perfusion deficit or new infarct) of incompletely reperfused tissue were included. Primary outcome was the rate of delayed reperfusion and its association with functional independence (modified Rankin Scale, mRS 0–2) at 90 days post-intervention. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects mode
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Check out the article, "Natural Evolution of Incomplete Reperfusion in Patients Following Endovascular Therapy After Ischemic Stroke," by @adnan_mujanovic et al, being presented at #SVIN24. #stroke #AHAJournals @SVINJournal @svinsociety https://t.co/vLcwkQKuqN
-
-
Mashup Score: 1
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions Hematology Disease Topics & Pathways: Research, Clinical trials, Combination therapy, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease Elias K. Mai, MD 1 *, Hans Salwender, MD 2 *, Michael Hundemer, MD 3 *, Uta Bertsch,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 GMMG-HD7 Trial (Isa-VRd vs. VRd induction) -More pts achieved MRDneg and continued MRDneg with Isa-VRd -Pts with MRDneg and continued MRDneg had longer PFS regardless of the induction arm #mmsm #bmtsm @EliasKarlMai https://t.co/hmsBhPnfK5
-
-
Mashup Score: 0Immunotherapy May Be Underused in Endometrial Cancer - 1 hour(s) ago
Suboptimal rates of dMMR testing and immunotherapy use suggest “a need for ongoing clinician and patient education, given the survival benefit of immunotherapy in recurrent endometrial cancer,” researchers concluded.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Immunotherapy and testing for mismatch repair deficiency may be underused in patients with #endometrialcancer in the United States, researchers say. Reported in @AJOG_thegray. https://t.co/Aot7gFgwN7 #gyncsm
-
-
Mashup Score: 12Marty Makary Seen as Leading Candidate for Trump FDA Nomination - 1 hour(s) ago
Surgeon and author Marty Makary is seen as the leading candidate to run the US Food and Drug Administration under President-elect Donald Trump, people familiar with the matter said.
Source: www.bloomberg.comCategories: General Medicine News, Infectious DiseaseTweet-
RT @GeBaiDC: Trump's Top Candidate for FDA Seen To Be @MartyMakary - Bloomberg https://t.co/jZtHi4pUHT
-
-
Mashup Score: 1Neuromorphic Camera Helps Drones Navigate GPS-free - 1 hour(s) ago
High-end positioning tech comes to low-cost UAVs
Source: spectrum.ieee.orgCategories: General Medicine News, General HCPsTweet-
INS and Neuromorphic Cameras Steer Drone for Post-GPS Tech - IEEE Spectrum https://t.co/C35jyTQs2j
-
-
Mashup Score: 24Caregiver-Reported Quality in Hospices Owned by Private Equity Firms and Publicly Traded Companies - 1 hour(s) ago
This study compares differences in caregiver-reported hospice quality across categories of ownership, including for-profit private equity firm (PEF)/publicly traded company (PTC)–owned and non-PEF/PTC–owned hospices as well as not-for-profit–owned hospices.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Surveyed caregivers of those who died on hospice had worse experiences including timely care and symptom management in hospices owned by private equity firms. 🏥💸⚕️More evidence that, when you run healthcare like a business, people suffer. https://t.co/LGfsU6VUL2 https://t.co/4W9l5XEKSG
-
-
Mashup Score: 5What have we learned about TP53-mutated acute myeloid leukemia? - 1 hour(s) ago
Blood Cancer Journal – What have we learned about TP53-mutated acute myeloid leukemia?
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
What have we learned about TP53-mutated acute myeloid leukemia? | Blood Cancer Journal @TalhaBadarMD @MKD_BMT @MayoCancerCare 👇🏽 https://t.co/n13nou4oQt
-
The FDA approved Tepezza in 2020 for treating TED following promising results from clinical trials. The results of 2 recent real-world studies show encouraging outcomes and indicate that the drug is performing well for a high percentage of patients https://t.co/8AAs8vwn9g https://t.co/WAFLmmuj3o